Limitations, agreements, and source contact

A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas · Source last updated 2025-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

point Of Contact

email

suzanne_george@dfci.harvard.edu

organization

Dana Farber Cancer Institute

phone

6176326826

title

Suzanne George MD, PI

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice